Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes (ALTO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01264263 |
Recruitment Status
:
Completed
First Posted
: December 21, 2010
Last Update Posted
: March 13, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Diabetes Mellitus Dyslipidemia |
Study Type : | Observational |
Actual Enrollment : | 181 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes |
Study Start Date : | January 2011 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | April 2011 |

Group/Cohort |
---|
1 |
- Measurement of intima media thickness, visit 1 [ Time Frame: Visit 1 ]
- Measurement of intima media thickness, visit 2 [ Time Frame: Visit 2 ]
- hs-C-Reactive Protein, visit 1 [ Time Frame: Visit 1 ]
- hs-C-Reactive Protein, visit 2 [ Time Frame: Visit 2 ]
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- patients with Diabetic Mellitus
- patients with dyslipidemia
Exclusion Criteria:
- patients who have established cardiovascular disease
- patient using NSAID

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01264263
Korea, Republic of | |
Research Site | |
Anyang, Korea, Republic of | |
Research Site | |
Koyang, Korea, Republic of | |
Research Site | |
Seoul, Korea, Republic of |
Study Chair: | Dongsun Kim | Hanyang University | |
Principal Investigator: | Eunkyung Hong | Hallym University Kangnam Sacred Heart Hospital | |
Principal Investigator: | Hyunsang Kwon | Yeoido Saint Mary's Hospital | |
Principal Investigator: | Dongjoon Kim | Ilsan-Paik Hospital | |
Principal Investigator: | Sungjin Lee | Hallym University Hospital | |
Principal Investigator: | Singon Kim | Korea University Anam Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT01264263 History of Changes |
Other Study ID Numbers: |
NIS-CKR-DUM-2010/1 |
First Posted: | December 21, 2010 Key Record Dates |
Last Update Posted: | March 13, 2012 |
Last Verified: | March 2012 |
Keywords provided by AstraZeneca:
cIMT hs CRP (C-reactive protein) DM (Diabetic Mellitus) |
Korea Corelation between cIMT (carotid intima media thickness) Cardio Vascular risk in Diabetic Mellitus |
Additional relevant MeSH terms:
Diabetes Mellitus Atherosclerosis Dyslipidemias Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Lipid Metabolism Disorders |